EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Onnamides A and B Suppress Hepatitis B Virus Transcription by Inhibiting Viral Promoter Activity

Yasuhiro Hayashi, Sei Arizono, Nanami Higa, Trianda Ayuning Tyas, Yuichi Akahori, Kenji Maeda iD, Masaaki Toyama, Kanami Mori-Yasumoto iD, Mina Yasumoto-Hirose, Kei Miyakawa, Junichi Tanaka iD, Takahiro Jomori iD

Marine Drugs · 2026

DOI: 10.3390/md24010021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Marine Drugs, 2026. Verfasst von Yasuhiro Hayashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Agriculture, University of Miyazaki, 1-1 Gakuen-kibanadai-nishi, Miyazaki City 889-2192, Miyazaki, Japan. Hauptthemen laut MEDLINE: Hepatitis B virus, Antiviral Agents, Promoter Regions, Genetic, Viral Transcription. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Okinawa Innovation Ecosystem Joint Research Promotion Project, Kobayashi, Kobayashi Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We recently reported that onnamide A, a marine-derived natural compound isolated from the sponge Theonella sp., inhibits the entry process of SARS-CoV-2 infection. However, its antiviral activity against other viruses remains largely unexplored. Here, we investigated the effects of onnamide A and its structurally related analog, onnamide B, on hepatitis B virus (HBV) infection. Using iNTCP cells, a hepatoblastoma-derived cell line permissive to HBV infection, we found that onnamides A and B exhibited cytotoxicity, with CC50 values of 0.53 ± 0.10 μM and 2.37 ± 0.25 μM, respectively. Following HBV infection, the levels of total HBV RNA were significantly reduced by onnamide A (IC50 = 0.06 ± 0.01 μM) and onnamide B (IC50 = 0.23 ± 0.06 μM). Notably, both compounds markedly decreased the levels of HBV pregenomic RNA. Furthermore, significant inhibition was particularly evident when onnamide treatment was initiated after HBV infection. Consistent with these observations, onnamides did not affect HBV binding, entry, or covalently closed circular DNA formation, but they significantly suppressed HBV RNA transcription. In particular, the transcriptional activities driven by the core and X promoters were markedly inhibited by onnamide treatment. Taken together, our findings demonstrate that onnamides possess potent anti-HBV activity and highlight their potential as candidate compounds targeting HBV RNA transcription.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusAntiviral AgentsPromoter Regions, GeneticViral TranscriptionHumansAnimalsRNA, ViralVirus ReplicationCell Line, TumorTranscription, Genetic

Stichwörter der Autor:innen

hepatitis B virusonnamides A and Bviral transcription inhibition

Substanzen

Antiviral AgentsRNA, Viral

Autor:innen und Institutionen

  • Faculty of Agriculture, University of Miyazaki, 1-1 Gakuen-kibanadai-nishi, Miyazaki City 889-2192, Miyazaki, Japan.
  • Faculty of Science, University of the Ryukyus, 1 Senbaru, Nishihara City 903-0213, Okinawa, Japan.
  • Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 1-21-24 Korimoto, Kagoshima City 890-8544, Kagoshima, Japan.
  • Department of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
  • Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika-ku, Tokyo 125-8585, Japan.
  • Tropical Technology Plus, 12-75 Suzaki, Uruma City 904-2234, Okinawa, Japan.

ORCID-Profile: Kenji Maeda, Kanami Mori-Yasumoto, Junichi Tanaka, Takahiro Jomori

Förderung

  • Okinawa Innovation Ecosystem Joint Research Promotion Project
  • Kobayashi
  • Kobayashi Foundation

Zitieren

APA

Hayashi, Y., Arizono, S., Higa, N., Tyas, T. A., Akahori, Y., Maeda, K., Toyama, M., Mori-Yasumoto, K., Yasumoto-Hirose, M., Miyakawa, K., Tanaka, J., & Jomori, T. (2026). Onnamides A and B Suppress Hepatitis B Virus Transcription by Inhibiting Viral Promoter Activity. Marine Drugs. https://doi.org/10.3390/md24010021

Vancouver

Hayashi Y, Arizono S, Higa N, Tyas TA, Akahori Y, Maeda K, et al. Onnamides A and B Suppress Hepatitis B Virus Transcription by Inhibiting Viral Promoter Activity. Marine Drugs. 2026. doi:10.3390/md24010021

BibTeX
@article{Hayashi2026,
  author = {Hayashi, Yasuhiro and Arizono, Sei and Higa, Nanami and Tyas, Trianda Ayuning and Akahori, Yuichi and Maeda, Kenji and Toyama, Masaaki and Mori-Yasumoto, Kanami and Yasumoto-Hirose, Mina and Miyakawa, Kei and Tanaka, Junichi and Jomori, Takahiro},
  title = {Onnamides A and B Suppress Hepatitis B Virus Transcription by Inhibiting Viral Promoter Activity},
  journal = {Marine Drugs},
  year = {2026},
  doi = {10.3390/md24010021}
}
Kostenlos starten →